What did Pfizer (PFE) disclose about Albert Bourla’s latest equity-related award?

Pfizer reported that Chairman & CEO Albert Bourla received 21 Phantom Stock Units valued at $28.08 each. The grant was made under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and increases his total phantom unit holdings to 759,049.

Pfizer CEO granted 21 phantom stock units

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 21 Phantom Stock Units on March 31, 2026 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is valued at $28.08 per unit.

These units are settled in cash after his separation from service and can be reallocated by him into another investment option at any time. Following this award, Bourla holds a total of 759,049 Phantom Stock Units directly.

Insider Trade Summary

Grant/Award: 21 shares

Grant/Award 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP	21	$28.08	$589.68

Holdings After Transaction: Phantom Stock Units SSP — 759,049 contracts (Direct)

Footnotes (2)

F1. Each unit represents one phantom share of common stock.
F2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Key Figures

Phantom Stock Units granted: 21 units Grant value per unit: $28.08 per unit Total phantom units after grant: 759,049 units +1 more

4 metrics

Phantom Stock Units granted 21 units Grant on March 31, 2026

Grant value per unit $28.08 per unit Phantom Stock Units SSP

Total phantom units after grant 759,049 units Bourla’s holdings following transaction

Underlying common stock equivalent 21 shares Each unit represents one phantom share of common stock

Key Terms

Phantom Stock Units, Nonfunded Deferred Compensation and Supplemental Savings Plan, separation from service, phantom share

4 terms

Phantom Stock Units financial

"Each unit represents one phantom share of common stock."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Nonfunded Deferred Compensation and Supplemental Savings Plan financial

"These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash"

separation from service financial

"are settled in cash following the reporting person's separation from service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Phantom Stock Units in Pfizer (PFE)’s compensation plans?

Pfizer’s Phantom Stock Units are bookkeeping units, each representing one phantom share of common stock. They are not actual shares; instead, they are settled in cash after the executive’s separation from service, following the terms of the deferred compensation plan.

How and when will Albert Bourla’s new Phantom Stock Units from Pfizer (PFE) be settled?

The 21 Phantom Stock Units granted to Albert Bourla will be settled in cash after his separation from service. The units are part of Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan, which specifies cash settlement rather than delivery of common shares.

Can Albert Bourla change how his Pfizer (PFE) Phantom Stock Units are invested?

Yes. The filing states that Bourla may transfer these Phantom Stock Units into an alternative investment account at any time. This flexibility applies to units held under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan, while they remain outstanding before cash settlement.

How large is Albert Bourla’s total Phantom Stock Unit position at Pfizer (PFE)?

After this latest grant of 21 Phantom Stock Units, Albert Bourla holds 759,049 Phantom Stock Units directly. Each unit tracks the value of one phantom share of Pfizer common stock and is ultimately settled in cash under the deferred compensation plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/01/2026 - 05:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units SSP	⁽¹⁾	03/31/2026		A		21		⁽²⁾	⁽²⁾	Common Stock	21	$28.08	759,049	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Pfizer CEO granted 21 phantom stock units

Rhea-AI Filing Summary

Positive

Negative